Drug Profile
Research programme: K 252a derivatives - Bio3 Research/Sienna Biopharmaceuticals
Alternative Names: CT 335; CT 336; K252a derivativesLatest Information Update: 15 Dec 2016
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Antiallergics; Carbazoles
- Mechanism of Action HMGB1 protein inhibitors; Protein tyrosine kinase inhibitors; TrkA receptor antagonists; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Behcet's syndrome; Coronary artery restenosis; Psoriasis
Most Recent Events
- 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
- 14 Apr 2010 Discontinued - Preclinical for Behcet's syndrome in Italy (Parenteral)
- 14 Apr 2010 Discontinued - Preclinical for Coronary artery restenosis in Italy (Parenteral)